Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2025-04-25 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 Annual Report" of Tuoxin Pharmaceutical Group Co., Ltd. It contains detailed sections including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and a full financial report. The document includes audited financial statements, signatures of responsible officers, and an audit report from a certified accounting firm. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content matches the description of an official yearly report covering company activity and full financial performance, which corresponds to the Annual Report (10-K) filing type. FY 2024
2025-04-25 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司2024年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion report from Zhongtian Guofu Securities Co., Ltd. regarding the 2024 annual verification of the storage and use of raised funds by Tuoxin Pharmaceutical Group Co., Ltd. It details the amount of funds raised, their usage, storage, management, and compliance with regulatory requirements. The document includes detailed financial figures related to fundraising and usage, references to regulatory guidelines, and audit opinions from the sponsoring institution. The content focuses on the verification and management of funds raised through an IPO and their subsequent use, which aligns with the characteristics of an Audit Report / Information document rather than a full Annual Report or other categories. It is not a report publication announcement since it contains substantive financial and compliance details, nor is it a certification or a brief announcement. Therefore, the document fits best under the Audit Report / Information (AR) category. FY 2024
2025-04-25 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司2024年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by a sponsoring institution (中天国富证券有限公司) regarding 拓新药业集团股份有限公司. It details the sponsor's supervision work, including review of company disclosures, governance, fundraising supervision, and internal compliance checks. It also reports on regulatory measures taken by the China Securities Regulatory Commission (CSRC) against the sponsor and the sponsor's corrective actions. The document is a detailed supervisory report rather than a financial statement or earnings release. It does not contain financial statements or earnings highlights but focuses on regulatory compliance, supervision, and governance oversight. This fits the definition of an Audit Report / Information (AR), which includes results of internal or regulatory stress tests and applied accounting principles, excluding full annual reports. The document length is 2758 characters, which is relatively short but contains substantive supervisory content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-25 Chinese
关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of the company 拓新药业集团股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on (including the 2024 annual report, board reports, financial statements, profit distribution plan, remuneration plan, internal control report, and auditor reappointment), registration details, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather serves as an official notification to shareholders about the AGM and the matters to be voted on. The length is about 5264 characters, which is consistent with a detailed AGM notice. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-25 Chinese
关于2024年年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by the company in the year 2024. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to the management and use of raised funds. The content includes specifics on the amount raised, usage, balance, changes in project implementation, and compliance with regulatory requirements. It is a specialized report focusing on the management and use of fundraising proceeds, not a general annual report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document length is substantial (over 12,000 characters) and contains detailed financial and project information, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-04-25 Chinese
关于2024年度不进行利润分配的专项说明的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding its 2024 annual profit distribution plan, specifically stating that no dividends will be distributed due to a net loss in 2024. It includes details about the board and supervisory committee meetings that approved the proposal, references the 2024 audit report, and explains the rationale behind the decision. The document is relatively short (2112 characters) and serves as a formal announcement of the profit distribution plan rather than the full annual report or audit report itself. It does not contain comprehensive financial statements or detailed financial analysis but rather the results of board decisions and a summary of the profit distribution plan. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about profit distribution and related board approvals, not the full annual report or audit report.
2025-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.